Precision oncology expert Dr. Ben Ho Park sheds light on cancer treatment innovations.
News: June, 2019
The nature of childhood cancer is different than adult cancer, and so is the approach to treatment.
A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work
Larry Marnett and colleagues have developed what may become the first agent for targeted PET imaging of cancer tissues, such as ovarian cancer, that express high levels of the COX-1 enzyme.
Fish oil supplementation provides a modest but beneficial effect on reducing molecules associated with colorectal cancer development.
Understanding how a steroid-metabolizing enzyme binds to its substrates may aid in designing drugs to treat sexual dysfunction as well as prostate cancer.
More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.
The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment.
Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).
Biomarkers of DNA methylation, which regulate gene expression, can be a predictor of breast cancer risk, according to a study published in Journal of the National Cancer Institute.